These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35852467)

  • 1. Scientific and Regulatory Policy Committee Points to Consider: Integration of Clinical Pathology Data With Anatomic Pathology Data in Nonclinical Toxicology Studies.
    Siska W; Schultze AE; Ennulat D; Biddle K; Logan M; Adedeji AO; Arndt T; Aulbach AD
    Toxicol Pathol; 2022 Aug; 50(6):808-826. PubMed ID: 35852467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scientific and Regulatory Policy Committee Points to Consider: Integration of Clinical Pathology Data With Anatomic Pathology Data in Nonclinical Toxicology Studies.
    Siska W; Schultze AE; Ennulat D; Biddle K; Logan M; Adedeji AO; Arndt T; Aulbach A
    Vet Clin Pathol; 2022 Sep; 51(3):311-329. PubMed ID: 35975895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scientific and Regulatory Policy Committee Points to Consider*: Review of Scientific and Regulatory Policy Committee Points to Consider: Review of Current Practices for Ultrastructural Pathology Evaluations in Support of Nonclinical Toxicology Studies.
    Keirstead ND; Janovitz EB; Meehan JT; LeRoy BE; Megill JR; Peterson RA; Masson RG; Marxfeld HA
    Toxicol Pathol; 2019 Jun; 47(4):461-468. PubMed ID: 31018785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scientific and Regulatory Policy Committee Points to Consider Review: Inclusion of Reproductive and Pathology End Points for Assessment of Reproductive and Developmental Toxicity in Pharmaceutical Drug Development.
    Halpern WG; Ameri M; Bowman CJ; Elwell MR; Mirsky ML; Oliver J; Regan KS; Remick AK; Sutherland VL; Thompson KE; Tremblay C; Yoshida M; Tomlinson L
    Toxicol Pathol; 2016 Aug; 44(6):789-809. PubMed ID: 27235322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scientific and Regulatory Policy Committee Points to Consider: Primary Digital Histopathology Evaluation and Peer Review for Good Laboratory Practice (GLP) Nonclinical Toxicology Studies.
    Forest T; Aeffner F; Bangari DS; Bawa B; Carter J; Fikes J; High W; Hayashi SM; Jacobsen M; McKinney L; Rudmann D; Steinbach T; Schumacher V; Turner O; Ward JM; Willson CJ
    Toxicol Pathol; 2022 Jun; 50(4):531-543. PubMed ID: 35657014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology Studies.
    McDorman KS; Bennet BM; Colman K; Fikes JD; Keirstead ND; Lanning Retired L; Munch B; Romeike A; Schafer KA; Schorsch F; Thibodeau MS; Thomas HC; Troth S; Vahle JL; Geoly FJ
    Toxicol Pathol; 2024 Feb; 52(2-3):138-148. PubMed ID: 38840532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scientific and Regulatory Policy Committee Points to Consider*: Approaches to the Conduct and Interpretation of Vaccine Safety Studies for Clinical and Anatomic Pathologists.
    Sellers RS; Nelson K; Bennet B; Wolf J; Tripathi N; Chamanza R; Perron Lepage MF; Adkins K; Laurent S; Troth SP
    Toxicol Pathol; 2020 Feb; 48(2):257-276. PubMed ID: 31594486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interpreting and Integrating Clinical and Anatomic Pathology Results.
    Ramaiah L; Hinrichs MJ; Skuba EV; Iverson WO; Ennulat D
    Toxicol Pathol; 2017 Jan; 45(1):223-237. PubMed ID: 27879439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scientific and Regulatory Policy Committee Brief Communication: 2019 Survey on Use of Digital Histopathology Systems in Nonclinical Toxicology Studies.
    Forest T; Aeffner F; Bangari DS; Bawa B; Carter J; Fikes J; High WB; Hayashi SM; Jacobsen M; McKinney L; Rudmann D; Steinbach T; Schumacher V; Turner OC; Ward JM; Willson CJ
    Toxicol Pathol; 2022 Apr; 50(3):397-401. PubMed ID: 35321602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interpretative considerations for clinical pathology findings in nonclinical toxicology studies.
    Aulbach A; Vitsky A; Arndt T; Ramaiah L; Logan M; Siska W; Cregar L; Tripathi N; Adedeji A; Provencher A; Gupta A; Jordan H; Bounous D; Boone L
    Vet Clin Pathol; 2019 Sep; 48(3):383-388. PubMed ID: 31549731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview and considerations for the reporting of clinical pathology interpretations in nonclinical toxicology studies.
    Aulbach A; Vitsky A; Arndt T; Ramaiah L; Logan M; Siska W; Cregar L; Tripathi N; Adedeji A; Provencher A; Gupta A; Jordan H; Bounous D; Boone L
    Vet Clin Pathol; 2019 Sep; 48(3):389-399. PubMed ID: 31556157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pathology testing recommendations for nonclinical toxicity and safety studies.
    Evans GO
    Toxicol Pathol; 1993; 21(5):513-4. PubMed ID: 8115827
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of Severity Grades to Characterize Histopathologic Changes.
    Schafer KA; Eighmy J; Fikes JD; Halpern WG; Hukkanen RR; Long GG; Meseck EK; Patrick DJ; Thibodeau MS; Wood CE; Francke S
    Toxicol Pathol; 2018 Apr; 46(3):256-265. PubMed ID: 29529947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scientific and Regulatory Policy Committee Points to Consider for Medical Device Implant Site Evaluation in Nonclinical Studies.
    O'Brien MT; Schuh JCL; Wancket LM; Cramer SD; Funk KA; Jackson ND; Kannan K; Keane K; Nyska A; Rousselle SD; Schucker A; Thomas VS; Tunev S
    Toxicol Pathol; 2022 Jun; 50(4):512-530. PubMed ID: 35762822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scientific and Regulatory Policy Committee Best Practices: Documentation of Sexual Maturity by Microscopic Evaluation in Nonclinical Safety Studies.
    Vidal JD; Colman K; Bhaskaran M; de Rijk E; Fegley D; Halpern W; Jacob B; Kandori H; Manickam B; McKeag S; Parker GA; Regan KS; Sefing B; Thibodeau M; Vemireddi V; Werner J; Zalewska A
    Toxicol Pathol; 2021 Jul; 49(5):977-989. PubMed ID: 33661059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anatomic pathology data generation in preclinical toxicology evaluation: Troubleshooting and risk management for toxicologists.
    Neef N; McInnes E
    Toxicol Lett; 2019 Oct; 314():164-171. PubMed ID: 31330168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International recommendations for training future toxicologic pathologists participating in regulatory-type, nonclinical toxicity studies.
    Bolon B; Barale-Thomas E; Bradley A; Ettlin RA; Franchi CA; George C; Giusti AM; Hall R; Jacobsen M; Konishi Y; Ledieu D; Morton D; Park JH; Scudamore CL; Tsuda H; Vijayasarathi SK; Wijnands MV
    Exp Toxicol Pathol; 2011 Jan; 63(1-2):187-95. PubMed ID: 20724123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International recommendations for training future toxicologic pathologists participating in regulatory-type, nonclinical toxicity studies.
    Bolon Chair B; Barale-Thomas E; Bradley A; Ettlin RA; Franchi CA; George C; Giusti AM; Hall R; Jacobsen M; Konishi Y; Ledieu D; Morton D; Park JH; Scudamore CL; Tsuda H; Vijayasarathi SK; Wijnands MV
    Toxicol Pathol; 2010 Oct; 38(6):984-92. PubMed ID: 20716784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scientific and Regulatory Policy Committee Points to Consider*: The Toxicologic Pathologist's Role in the 3Rs.
    Hukkanen RR; Dybdal N; Tripathi N; Turner PV; Troth SP
    Toxicol Pathol; 2019 Oct; 47(7):789-798. PubMed ID: 31648619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies.
    Moffit JS; Blanset DL; Lynch JL; MacLachlan TK; Meyer KE; Ponce R; Whiteley LO
    Hum Gene Ther; 2022 Nov; 33(21-22):1126-1141. PubMed ID: 35994386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.